Figures & data
Figure 1. The molecular formulation of resveratrol.
Figure 2. Impact trend graph of: (a) CMCS concentration, (b) the volume ratio of water and chloroform, (c) the ratio of Tween-80 and water, (d) homogenized time, (e) the pressure of high-pressure homogenization and (f) the time of high-pressure homogenization to CMCSNPs size.
Figure 3. Impact trend graph of CaCl2 concentration to size, zeta potential, drug loading and encapsulation efficiency of RES-CMCSNPs. (a) Size, (b) zeta potential, (c) drug loading and (d) encapsulation efficiency.
Figure 4. Different multiples morphology of RES-CMCSNPs: (a) without homogenization (10 × 10) and (b) after homogenization (10 × 10).
Figure 5. Scanning electron micrograph: (a) RES raw powder, (b) CMCS, (c) RES-CMCSNPs and (d) RES-CMCSNPs with mannitol.
Figure 6. Infrared spectrogram: (a) RES raw powder, (b) CMCS, (c) RES-CMCSNPs and (d) RES-CMCSNPs with mannitol.
Figure 7. XRD pattern: (a) RES raw powder, (b) CMCS, (c) RES-CMCSNPs, (d) RES-CMCSNPs with mannitol and (e) mannitol.
Figure 8. DSC thermogram: (a) RES raw powder, (b) CMCS, (c) RES-CMCSNPs and (d) RES-CMCSNPs with mannitol.
Figure 9. Gas chromatograms of samples: (a) chloroform standard solution and (b) RES-CMCSNPs.
Figure 10. DPPH radical scavenging rate. (a) RES raw powder, (b) RES-CMCSNPs with CMCSNPs as control, (c) RES-CMCSNPs and (d) CMCSNPs.
Figure 11. Release profile in simulated gastric fluid. (a) RES raw powder and (b) RES-CMCSNPs.
Figure 12. Release profile in simulated intestinal fluid. (a) RES raw powder and (b) RES-CMCSNPs.
Figure 13. Concentration–time curve. (a) RES raw powder and (b) RES-CMCSNPs.
